Skip to content

Septerna, Inc. SEPN Deferred Revenue

Deferred Revenue at other companies

Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$6.6M-35.6%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$18.75M-38.7%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
$481.3M+32.1%
Precigen logo
PrecigenPGEN
$410K-25.3%
Arrowhead Research logo
Arrowhead ResearchARWR
$108.54M+151%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$69.2M-14.7%

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Cash & equivalents$71.6M-65.9%
Total debt$23.1M-7.7%
Total equity$378.5M+195%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.65B+319%
Enterprise value$1.6B+1,325%
P/S22.8×-379×

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Return on equity-12.2%
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Reported directly by Septerna, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.

The official record: Septerna, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Septerna, Inc.'s deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Septerna, Inc.'s deferred revenue?
Septerna, Inc. (SEPN) reported deferred revenue of $59.76M in Q1 2026.
What does deferred revenue mean?
Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.